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The integrin avb6 is a ®bronectin receptor whose
expression is not detectable on normal oral epithe-
lium but is increased signi®cantly in healing and in
oral epithelial dysplasia and oral squamous cell car-
cinoma, suggesting it may promote changes associ-
ated with tumor development. To study whether
avb6 may drive invasive behavior we have used
transfection and retroviral infection to create a panel
of epithelial cell lines expressing various levels of
avb6. We report that increased expression of avb6 in
malignant keratinocytes promotes invasion and leads
to an increased capacity for migration towards ®bro-
nectin. avb6 expression may have a signi®cant role
in contributing to the malignant behavior of epithe-
lial cells. Key words: integrins/invasion/keratinocytes/
migration. J Invest Dermatol 117:67±73, 2001
I
ncreased epithelial mobility and migration play a funda-
mental role in normal and pathologic processes such as
development, wound healing, and malignant transforma-
tion. Most dramatically this is seen in carcinogenesis, where
epithelial cells cross the basement membrane and proliferate
and migrate within the connective tissues. The process of invasion
involves altered cell±cell and cell±matrix interactions, loss of
growth control, and acquisition of the ability to degrade and
invade stromal tissues. Frequently these changes are accompanied
by altered expression of cell adhesion molecules, of which the
integrins are the most important extracellular matrix (ECM)
receptors (Juliano and Varner, 1993; Giancotti and Mainiero,
1994; Ben-Ze'ev, 1997).
Worldwide, oral squamous cell carcinoma (SCC) is the sixth
most common cancer, representing about 5.5% of all malignancies
(Parkin et al, 1993). In the U.K. there are over 3000 new cases each
year with a mortality rate that has remained at over 50% for decades
and is not improving (Johnson and Warnakulasuriya, 1993; Hindle
et al, 1996). One integrin heterodimer, avb6, is not expressed in
normal epithelium but is consistently found in oral epithelial
dysplasia and oral SCC, suggesting it may play a role in the
development and progression of such tumors.
Integrins are transmembrane cell surface receptors, composed of
noncovalently linked heterodimers of a and b chains (Hynes, 1992;
Sonnenberg, 1993). Integrins mediate adhesion to the ECM and
function as coordinators of signaling pathways that regulate a
diverse range of cell functions including motility, proliferation,
differentiation, and apoptosis (Hynes, 1992; Sonnenberg, 1993;
Frisch and Francis, 1994; Clark and Brugge, 1995; Yamada, 1997).
These intracellular signals are generated as a result of ligand binding
and in this way cells may respond to ECM-speci®c interactions
(Damsky and Werb, 1992). Different integrins generate different
signals and some of these may have profound effects on the biologic
behavior of tumors.
De novo expression of avb6 is seen in a number of epithelial
malignancies, particularly oral SCC, which may be correlated with
a downregulation of avb5 (Agrez et al, 1996; Jones et al, 1997).
More recently, Hamidi et al (2000) found that avb6 was expressed
in a high percentage of oral epithelial dysplasias where it correlated
with disease progression, suggesting that it may promote transition
to a malignant phenotype. Intriguingly, increased avb6 expression
also is seen on wound keratinocytes suggesting that avb6 normally
plays a role in tissue repair and/or remodeling (Haapasalmi et al,
1996).
To address the potential role of avb6 in oral SCC, we have
examined the functional signi®cance of high avb6 expression using
a range of SCC cell lines, which have been created by transfection
and retroviral infection. We report that increased expression of
avb6 promotes invasion and leads to an increased capacity for
migration towards ®bronectin, perhaps suggesting that avb6 may
have a role in tumor progression and may enhance the aggressive
behavior of carcinoma.
MATERIALS AND METHODS
Antibodies and reagents Eight monoclonal antibodies (all of murine
origin unless stated) were used in this study. L230 (antihuman av) was
prepared in our laboratory from hybridoma cells obtained from the
American Type Culture Collection (Rockville, MD) (Weinacker et al,
1994). E7P6 and R6G9 against the b6 subunit (Weinacker et al, 1994)
and 10D5 against avb6 (Huang et al, 1998) were prepared in the
laboratories of Dean Sheppard. P1F6 against avb5 was obtained from
Life Technologies, Paisley, U.K. P1D6 against a5b1 was purchased from
Chemicon International (Harrow, U.K.). Fluorescein isothiocyanate
(FITC) conjugated rabbit antimouse antibodies were purchased from
Dako (High Wycombe, U.K.). Geneticin (neomycin analog G418),
puromycin, type I collagen, cellular ®bronectin, and bovine serum
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albumin (BSA) were purchased from Sigma Chemical (Poole, Dorset,
U.K.). Magnetic beads (Dynabeads) conjugated to antimouse antibody
were purchased from Dynal (Merseyside, U.K.). Matrigel was purchased
from Becton Dickinson (Oxford, U.K.).
Cell cultures We created a panel of cell lines expressing various levels
of avb6. The V3 cell line was generated from an av-negative oral SCC
line (H357; Prime et al, 1990; Sugiyama et al, 1993) by transfection of
av cDNA (Jones et al, 1996). V3 cells predominantly express the avb5
heterodimer. Cells were grown in standard keratinocyte growth medium
(KGM) as described previously (Sugiyama et al, 1993; Jones et al, 1996).
KGM comprised a modi®ed Eagle's medium (a-MEM) containing 10%
fetal bovine serum (FBS; Globepharm, Surrey, U.K.) supplemented with
100 IU per l penicillin, 100 mg per l streptomycin, 2.5 mg per l
amphotericin B (Gibco BRL), 1.8 3 10±4 M adenine, 5 mg per ml
insulin, 1 3 10±10 M cholera toxin, 0.5 mg per ml hydrocortisone, and
10 ng per ml epidermal growth factor (Sigma). G418 was added to the
transfected cells during routine culture (2 mg per ml) but removed for
experimental procedures. All cells were tested routinely for mycoplasma.
Creation of a high avb6 expressing cell line by retroviral infection
of V3 cell line with b6 b6 cDNA was polymerase chain reaction
subcloned from the plasmid pcDNA1neob6, containing the complete
cDNA sequence of the human b6 subunit, into Pcr2.1 (In Vitrogen),
from where it was excised with EcoR1 and ligated into the EcoR1 site
of the retroviral plasmid pBabe puro (Morgenstern and Land, 1990).
Maxiprep DNA of pBabe puro/b6 and also (as control) pBabe puro was
transfected into the AM12 amphotrophic retroviral packaging cell line,
using Promega Tfx transfection kit. Transfected cells were selected in
puromycin (1.75 mg per ml). Prior to harvesting retroviruses,
puromycin-free growth medium was added to the AM12-puro and
AM12-purob6 cells for 24 h. To retrovirus-containing medium,
hexadimethrine bromide (Sigma) was added (4 mg per ml) and the
mixture was ®ltered through a 0.45 mm sterile ®lter. Target cells (V3)
were exposed to the ®ltered, retrovirus-containing conditioned medium
for 16±20 h. Medium was replaced with fresh for 24 h before selecting
cells by adding puromycin (0.75 mg per ml). Resistant cells expressing b6
were evident 3±4 d after puromycin selection. As controls, null-
transfectants (C1 cells) were created by infection with the retroviral
vector (pBabe puro) alone. A population of b6-expressing cells were
selected by two rounds of magnetic bead sorting according to
manufacturer's instructions (Dynabeads, Dynal) using mouse anti-b6
antibody E7P6. These cells were called VB6.
Flow cytometry Subcon¯uent cells were washed twice with
phosphate-buffered saline (PBS) and harvested by trypsin/ethylene-
diamine tetraacetic acid (EDTA) (0.25% wt:vol, 5 mM). Cells were
washed once in PBS containing 10% FBS. Cells were incubated with
primary antibody for 40 min at 4°C and washed twice with PBS. FITC-
conjugated secondary antibody was applied to the cells for 30 min at
4°C. Brie¯y, cells were washed twice with PBS and resuspended in
0.5 ml PBS with 10% FBS. Labelled cells were scanned on a
FACSCalibur cytometer (Becton Dickinson) and analyzed using
Cellquest software, acquiring 1 3 104 events.
Immunoprecipitation Cells were surface-iodinated with [125I] using
the lactoperoxidase method as described previously (Marshall et al, 1991).
Cells were washed in cold PBS supplemented with 1 mM Ca2+ and
0.5 mM Mg2+ and lyzed with Nonidet P-40 lysis buffer (20 mM
HEPES, 1% Nonidet P-40, 50 mM NaCl, 1 mM CaCl2, 3 mM MgCl2,
0.3 M sucrose, 0.1% sodium azide), supplemented with protease
inhibitors (leupeptin 100 mg per ml, phenylmethylsulfonyl ¯uoride
100 mg per ml, aprotinin 100 mg per ml). Lysates were cleared by
centrifugation at 13,000g for 10 min. Protein-incorporated 125I was
determined by trichloroacetic acid (TCA) precipitation of 2 ml samples of
lysates which were then diluted with lysis buffer to give equal TCA-
precipitable [125I] per unit volume. To equal volumes of lysate was
added TS2/16 (anti-b1, 6 mg), L230 (anti-av, 9 mg), or P2W7 (anti-av,
10 mg), followed by rabbit antimouse IgG (Dako Z259). Protein A-
sepharose (50 ml of 1:1 suspension in lysis buffer; Amersham Pharmacia
Biotech, Little Chalfont, U.K.) was added and samples were tumbled
overnight at 4°C. Precipitated complexes were boiled for 10 min in
nonreducing buffer (0.5 M Tris-HCl pH 6.8, 10% sodium dodecyl
sulfate, 10% glycerol, 0.4% bromophenol blue), and separated on 10%
acrylamide gels. Gels were ®xed and dried before exposure to ®lm
(Kodak XAR-5) at ±80°C for up to 6 d.
Adhesion assays Ninety-six-well plates (Falcon 3912; Becton
Dickinson) were coated with plasma ®bronectin (Sigma). A 50 ml
solution at a concentration of 10 mg per ml (®bronectin) was added to
the wells and incubated at 37°C for 1 h. After incubation wells were
washed with PBS and then blocked with 0.1% BSA at 37°C for 30 min.
Control wells were incubated with 0.1% BSA. Cells were chromium
[51Cr] labeled (Brunner et al, 1976), washed, and resuspended in
a-MEM (1.5 3 104 cells per well). For blocking experiments, cells were
incubated with speci®c antibodies (as described in Results) for 10 min on
ice in each well. Plates were incubated at 37°C for 1 h. Non-adherent
cells were removed by ¯ooding plates with PBS (supplemented with
1 mM CaCl2 and 0.5 mM MgCl2). After two washes, the plates were
cut into individual wells and the radioactivity associated with each well
was determined in a gamma counter (1261 Multigamma; LKB Wallac,
Bromma, Sweden). The percent adhesion was expressed as the adherent
cell radioactivity as a proportion of the total cell input. The nonspeci®c
adhesion (attachment to wells coated with BSA) was subtracted.
Experiments were repeated on three occasions in quadruplicate, with
similar results.
Immunolocalization of avb6 2 3 104 cells were plated onto 13 mm
glass coverslips coated with ®bronectin (10 mg per ml) and blocked with
0.1% BSA in PBS. Coverslips were incubated for 6, 9, and 24 h at 37°C
in 5% CO2. Cells were rinsed twice in PBS, ®xed for 15 min in 10%
formalin, and permeabilized with 0.1% Triton X-100 for 10 min,
followed by incubation for 60 min in PBS containing 0.1% BSA. L230
(18 mg per ml) or R6G9 (1:10 dilution of supernatant:wash buffer)
diluted in PBS containing 0.1% BSA with 0.1% azide was added for
60 min at 4°C. Bound antibody was detected with FITC-conjugated
rabbit antimouse secondary antibody (Dako; 1:40). Actin was visualized
with TRITC-conjugated phalloidin (Sigma: 5 ng per ml). Coverslips
were washed three times for 5 min in wash buffer and mounted with
MOWIOL 4±88 (Novabiochem, Nottingham, U.K.: 0.1 g per ml of
Citi¯uor mounting medium) and viewed with a confocal laser scanning
microscope (Zeiss LSM510; Welwyn Garden City, U.K.).
Proliferation assays Cells were grown on uncoated or matrigel-
coated six-well plates for 160 h. Prior to plating, wells were coated with
matrigel (1:20 dilution in a-MEM) for 1 h at 37°C and blocked with
a-MEM containing 0.5% BSA for a further 30 min. Cells were also
grown within matrigel gels (1:2 dilution in a-MEM). 2 3 104 cells were
plated into each well and fed every 3 d. Cells were removed from
triplicate wells by trypsinization or gel digestion with Matrisperse
(Becton Dickinson, Bedford, U.K.) and counted on a Casy 1 counter
Table I. Flow cytometric analysis of keratinocyte cell lines derived from oral SCCa
a1 a2 a3 a4 a5 a6 av b1 b4 avb3 avb5 avb6
H357 ND 142.4 181.8 ND 8.7 581.0 ND 270.1 199.0 ND ND ND
V3 ND 170.5 211.3 ND 8.18 662.3 12.6 346.3 201.0 ND 5.3 1.8
VB6 ND 163.4 165.5 ND 9.1 689.7 157.1 383.2 229.7 ND 6.8 174.6
C1 ND 146.4 210.9 ND 10.9 542.0 7.2 338.1 218.0 ND 2.4 2.5
aCell lines H357, V3, VB6, and C1 were detached by trypsin/EDTA and immunolabeled with antibodies to a1 (TS2/7), a2 (P1E6), a3 (P1B5), a4 (7.2), a5 (P1D6),
a6 (GOH3), b1 (TS2/16), b4 (3E1), av (L230), avb3 (LM609), avb5 (P1F6), or avb6 (E7P6). Bound antibody was detected by FITC-conjugated rabbit antimouse anti-
sera. Negative control had secondary antibody only and has been subtracted from the results. The table shows a representative experiment (ND = not detected). Flow cyto-
metry con®rmed high avb6 in the VB6 cells and showed that V3 and C1 cells express predominantly avb5. The null transfectant control C1 cells are the same as the V3
parentals con®rming that the transfection and infection processes had not altered levels of other integrins expressed by the cells. The integrin subunits a1, a4, and the avb3
heterodimer were not detectable in the cell lines. The av subunit or av heterodimers were not detectable in the original H357 cells.
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(Sharfe System, Germany). Readings were taken every day until day 10.
Experiments were repeated a minimum of four times in triplicate.
Migration assays Haptotactic cell migration assays were performed
using matrix-coated polycarbonate ®lters (8 mm pore size, Transwell;
Becton Dickinson). The membrane undersurface was coated with
®bronectin (10 mg per ml) or collagen I (50 mg per ml) in PBS for 1 h at
37°C and blocked with migration buffer (0.5% BSA in a-MEM) for
30 min at 37°C. For blocking experiments, cells were incubated with
antibody for 30 min at 4°C prior to seeding. The lower chamber was
®lled with 500 ml of migration buffer, following which cells were plated
in the upper chamber of triplicate wells, at a density of 1 3 105 in
100 ml of migration buffer, and incubated at 37°C for 3 h. Following
incubation, Transwell inserts were ®xed in 10% formalin, stained with
0.5% crystal violet in 10% ethanol for 10 min, and washed. Cells in the
upper compartment were removed using a cottonwool swab and the
®lter was mounted in DPX on a microscope slide. Cells, which had
migrated to the lower surface of the ®lter, were counted by microscopy,
using multiple random high-powered ®elds (at least six ®elds per ®lter as
determined by cumulative frequency analysis). Between 200 and 800
cells were counted routinely per ®lter. The experiments were repeated
four times in triplicate.
Invasion assays Cell invasion assays were performed using matrigel-
coated polycarbonate ®lters (8 mm pore size, Transwell; Becton
Dickinson). Matrigel (70 ml; 1:2 dilution in a-MEM) was added to the
upper membrane and allowed to gel for 1 h at 37°C. For blocking
experiments, cells were incubated with anti-integrin antibody for 30 min
at 4°C prior to seeding. Additional antibody was added to the assay at
24 h intervals. To act as a chemoattractant, 500 ml of KGM was placed
in the lower chamber. Cells were plated in the upper chamber of
quadruplicate wells at a density of 5 3 104 in 200 ml of a-MEM and
incubated at 37°C for 72 h. The cells in the lower chamber (including
those attached to the undersurface of the membrane) were then
trypsinized and counted on a Casy 1 counter (Sharfe System).
Experiments were repeated six times in quadruplicate. Adhesion assays
on matrigel were also carried out at this time to ensure that any
reduction of invasion produced by anti-integrin blocking antibodies was
not simply due to inhibition of initial cell attachment.
Statistical analysis Data are expressed as the mean 6 SD of a given
number of observations. Where appropriate, one way analysis of variance
was used to compare multiple groups. Comparisons between groups
were by Tukey's pairwise comparison (set at 5% signi®cance). A p-value
of < 0.05 was considered to be signi®cant.
RESULTS
The VB6 cell line expresses high levels of avb6 V3 cells were
infected with a retrovirus containing b6 cDNA to create VB6.
Flow cytometry con®rmed that the C1 null transfectants showed
Figure 1. VB6 cells do not express the avb1 heterodimer.
Immunoprecipitation of av and b1 integrins expressed by keratinocyte
cell lines derived from oral SCC. Antibodies against b1 or av were
added to Nonidet P-40 detergent lysates of surface-iodinated [125I]
H357, V3, VB6, and C1 cells. Immunocomplexes were captured with
rabbit antimouse IgG and protein A sepharose. Samples were separated
on 6% SDS-PAGE gels under nonreducing conditions. Gels were
exposed to XAR-5 ®lm. As b1 is expressed at very high levels it was
necessary to combine a short and a long exposure of the gel in order to
clearly see the electrophoretic mobility of the b1 subunit.
Immunoprecipitation with two different anti-av antibodies (L230,
P2W7) failed to coprecipitate b1.
Figure 2. VB6 cells adhere to ®bronectin using both avb6 and
a5b1. Adhesion of C1 (A) and VB6 (B) cells to ®bronectin. Chromium
[51Cr]-labeled cells (1.5 3 104) were added to ®bronectin-coated 96-
well plates containing an irrelevant control antibody (GOH3, 1:100 anti-
a6) or test antibodies against av (L230, 20 mg per ml), avb6 (10D5,
20 mg per ml), or a5b1 (P1D6, 1:100). Adhesion to ®bronectin of C1
and VB6 cells in the presence of GOH3 was 34% and 40%, respectively.
Background binding to BSA-coated wells was 14% and 13%,
respectively, and has been subtracted from the results. Results are
expressed relative to GOH3. Adhesion of C1 cells was blocked by
antibodies to a5b1 (P1D6) whereas a similar inhibition of adhesion of
VB6 cells required antibodies to both avb6 and a5b1. The ®gure shows
a representative experiment performed in quadruplicate. Error bars
represent standard deviation.
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unaltered av (or other integrin) expression compared with the V3
parental cells (Table I). Although a low level of avb6 was
expressed in C1 and V3 cells, the predominant av-containing
heterodimer was avb5, which we have shown previously to be a
functional vitronectin receptor (Jones et al, 1996). In contrast, avb6
expression on VB6 cells showed a 100-fold increase compared with
the V3 and C1 cells (Table I). The level of avb5 expression in
VB6 cells remained unaltered, as did the levels of the ®bronectin
receptor a5b1 and other integrins (Table I). Fluorescence-
activated cell sorter analysis also con®rmed that these cells do not
express avb3 (Table I).
In order to determine whether V3, VB6, and C1 cells expressed
avb1, another potential ®bronectin receptor, cells were analyzed
by immunoprecipitation. Figure 1 shows that immunoprecipit-
ation with two different anti-av antibodies failed to coprecipitate
b1. As a comparison, b1 integrins were immunoprecipitated with a
b1-speci®c antibody (TS2/16) and electrophoresed on the same
gel. Thus the combined results from ¯ow cytometry and
immunoprecipitation show that the only av integrins expressed
by V3, C1, and VB6 cells are avb5 and avb6 and that VB6 cells
express high levels of avb6.
Adhesion of VB6 cells to ®bronectin is mediated by a5b1
and avb6 To con®rm that avb6 in VB6 cells was functional, the
cell lines were plated onto ®bronectin in the presence or absence of
blocking antibodies against the av subunit (L230), avb6 (10D5),
a5b1 (P1D6), or an irrelevant antibody against a6 (GOH3).
Combinations of these antibodies were also used. Adhesion of C1
cells (Fig 2A) and V3 cells (data not shown) to ®bronectin could be
blocked using P1D6 alone. Maximal inhibition of VB6 adhesion to
®bronectin, however, required a combination of 10D5 and P1D6
(or L230 and P1D6) indicating that avb6 is functional and that the
VB6 cells bind to ®bronectin using both a5b1 and avb6 (Fig 2B).
Subcellular distribution of avb6 Immuno¯uorescence for b6
in VB6 cells showed that b6 colocalized with actin in focal
adhesions. This was con®rmed by colocalization of b6 with the
focal adhesion protein talin (data not shown).
Increased avb6 expression has no effect on cell growth on
uncoated or matrigel-coated tissue culture plastic The
growth rates of the V3, VB6, and C1 lines were compared on
uncoated versus matrigel-coated tissue culture plastic. Cell
proliferation was also measured within matrigel gels. G418 and
puromycin were removed from the medium for the duration of the
experiment. avb6 had no effect on cell growth on uncoated or
matrigel-coated tissue culture plastic, or within matrigel gels (data
not shown).
Increased expression of avb6 increases migration towards
®bronectin To determine whether avb6 is involved in keratino
cyte migration, haptotactic migration assays were performed using
®bronectin-coated Transwell ®lters. Over four separate experi-
ments, migration towards ®bronectin was signi®cantly increased in
VB6 cells compared with either V3 (p < 0.001) or C1 cells
(p < 0.001). Figure 4(A) shows a representative experiment. No
difference in migration was observed between the V3 parental cells
and C1 null transfectants. The cell lines showed no signi®cant
differences when migrating towards collagen I, con®rming that the
differences in migration potential were speci®c for ®bronectin
(Fig 4B).
The migration towards ®bronectin of V3 and C1 cells was
inhibited by 79% and 68%, respectively, using antibodies against
a5b1 (P1D6) (Fig 4C, D) but not by antibodies against the av
integrins (L230, P1F6, 10D5). In marked contrast, antibodies against
av (L230), avb6 (10D5), or a5b1 (P1D6) inhibited migration of the
VB6 cells (19%, 52%, and 31%, respectively) (Fig 4E). To block
migration completely, however, a combination of 10D5 and PID6
(or L230 and P1D6) was necessary. Migration towards ®bronectin in
the presence of P1D6 (anti-a5b1) in VB6 cells shows that avb6
alone is capable of mediating migration towards ®bronectin,
although to a lesser extent than when both receptors are available.
Increased expression of avb6 increases invasion through
matrigel To determine whether avb6 is involved in cell
invasion, cells resuspended in a-MEM were added to matrigel-
coated Transwell ®lters and allowed to invade for 72 h toward
KGM placed in the lower chamber. In six separate experiments,
invasion consistently was increased signi®cantly in VB6 cells
compared with V3 (p = 0.001) or C1 cells (p < 0.001). This
increased invasion was not due to differences in growth rates of cells
in matrigel, which were similar for all the SCC cell lines (data not
shown). No signi®cant difference in invasion was observed
between the V3 parental cell line and C1 null transfectants.
Figure 5(A) shows a representative experiment.
The invasion of V3 and C1 cells was inhibited by 61% and 65%,
respectively, using antibodies against a5b1 (P1D6) (Fig 5B, C) but
not by antibodies against the av integrins (L230, P1F6, 10D5). In
contrast, antibodies against av (L230) and avb6 (10D5) dramatic-
ally inhibited invasion of VB6 cells (77% and 73%, respectively)
whereas antibodies against a5 (P1D6) had no signi®cant effect
(Fig 5D). Invasion of matrigel by all cell lines could be blocked
with antibody against b1 (P4C10). Adhesion to matrigel in these
lines also, however, is blocked completely by anti-b1 (data not
shown) and it is probable that P4C10 inhibits cell attachment to
matrigel rather than invasion (10D5 has no effect on VB6 adhesion
to matrigel ± data not shown).
Figure 3. avb6 localizes to focal adhesions in VB6 cells. VB6 cells were plated onto ®bronectin-coated glass coverslips for 9 h. The b6 subunit
was detected with R6G9. Actin was detected by phalloidin-TRITC. Cells were examined on a confocal microscope and images were collected
digitally. The ®gure shows the actin (red image; left), avb6 (green image; middle), and the combined red and green images (right). Magni®cation bar,
10 mm. The panels show the colocalization of avb6 with actin in focal adhesions.
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DISCUSSION
To date there are few data available on the biologic role of avb6 in
oral SCC. As de novo expression of avb6 in oral epithelial dysplasia
and SCC has been implicated in disease progression we tested
whether induced increases in this heterodimer affected biologic
behavior of transformed keratinocytes. Using transfection and
retroviral infection we generated a series of SCC cell lines, derived
from a single av-negative precursor, which express varying levels of
avb6. We show that high avb6 expression is associated with a
more invasive and more migratory phenotype. As these processes
are fundamental to epithelial malignancy this may explain, in part,
how upregulation of avb6 in oral SCC (Breuss et al, 1995; Jones
et al, 1997) could promote malignant behavior.
Altered integrin expression occurs in many epithelial tumors
(Peltonen et al, 1989; Pignatelli et al, 1990; Hall et al, 1991; Koretz
et al, 1991; Downer et al, 1993; Jones et al, 1993; Thomas et al,
1997) and although these changes are not always consistent, certain
trends are evident. Loss of normally expressed integrins may be a
common ®nding, particularly in poorly differentiated lesions.
Conversely, other integrins, such as avb3, are upregulated
signi®cantly during the invasive stages of certain tumors like
melanoma and glioblastoma (Marshall and Hart, 1996).
Upregulation of avb6 in SCC suggests that this integrin has an
active role in tumor progression through inappropriate activity of
tissue repair mechanisms. At present, however, there are few data
on the biologic functions of avb6 in squamous cell or other
carcinomas. Neo-expression of avb6 in the SW480 colon
carcinoma cell line mediated ligand-independent signaling for
MMP-9 secretion (Niu et al, 1998), and Agrez et al (1994) reported
an avb6-dependent increase in proliferation in collagen gels by the
same cells, as well as enhanced xenograft growth in nude mice. In
contrast to these ®ndings high avb6 expression in VB6 cells did not
affect cell proliferation within matrigel. This suggests that enhanced
proliferation may be collagen I dependent but also raises the
possibility that the functional effect of avb6 expression may be cell-
type speci®c.
Figure 4. Increased expression of avb6 increases migration
towards ®bronectin. Cells were allowed to migrate towards ®bronectin
in haptotactic migration assays. After 3 h the samples were ®xed and the
cells were counted by microscopy. (A) Comparison of migration of V3,
VB6, and C1 cells towards ®bronectin (FN). (B) Comparison of
migration of V3, VB6, and C1 cells towards collagen I (COL I). To
assess integrin speci®city of migration, integrin-blocking antibodies
against av (L230), avb5 (P1F6), avb6 (10D5), and a5b1 (P1D6) were
added to V3 cells (C), C1 cells (D), and VB6 cells (E), prior to plating
into wells (results for both cell lines are expressed relative to an irrelevent
control antibody against class I MHC, W6/32 = 100). Figures show
representative experiments performed in triplicate. Error bars represent
standard deviation.
Figure 5. Increased expression of avb6 increases invasion through
matrigel. Cell invasion assays were performed over 72 h using matrigel-
coated polycarbonate ®lters. To assess integrin speci®city of invasion,
integrin-blocking antibodies against av (L230), avb6 (10D5) a5b1
(P1D6), and b1 (P4C10) were added to the cells. Further antibody was
added to the assay at 24 h intervals. Following incubation the cells in the
lower chamber (including those attached to the undersurface of the
membrane) were trypsinized and counted on a Casy 1 counter (Sharfe
System). The ®gures show representative experiments performed in
quadruplicate. Error bars represent standard deviation. (A) Comparison of
invasion between V3, C1, and VB6 cell lines. (B) Invasion of V3 cells
following incubation with anti-integrin antibodies. Results are expressed
relative to invasion following blockade with an irrelevant antibody
against class I MHC, W6/32 (= 100). (C) Invasion of C1 cells following
incubation with anti-integrin antibodies. Results are expressed relative to
invasion following blockade with an irrelevent control antibody against
MHC, W6/32 (= 100). (D) Invasion of VB6 cells following incubation
with anti-integrin antibodies. Results are expressed relative to invasion
following blockade with an irrelevent control antibody against MHC,
W6/32 (= 100).
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Several in vivo studies have suggested that upregulation of avb6
by keratinocytes in wounds and tumors is associated with
downregulation of avb5 (Clark et al, 1996; Jones et al, 1997)
possibly due, in part, to sequestering of all the available av subunits
as avb6 heterodimers. In contrast to these ®ndings, the levels of
avb5 expressed by VB6 cells were comparable to V3 and C1 cells.
As expression of av in these cells is controlled by a viral (CMV)
promoter, however, the av subunit is constitutively overexpressed
and therefore not a limiting factor for avb5 expression.
Effect of avb6 on cell migration Huang et al (1998)
demonstrated that avb6 mediated mouse keratinocyte migration
on ®bronectin and also on vitronectin substrates. In agreement with
these ®ndings, migration of VB6 cells towards ®bronectin was
signi®cantly higher than either V3 (p < 0.001) or C1 cells (p
< 0.001) (Fig 4A). VB6 cells adhered and migrated on ®bronectin
using both avb6 and a5b1, and migration towards ®bronectin
could only be blocked completely using antibodies against both
integrins (Fig 4E). It is not yet evident whether these integrins
cooperate in the VB6 cells or whether one is used preferentially.
Migration towards ®bronectin in V3 and C1 cells was abolished by
antibodies against a5b1 (Fig 4C, D). Adhesion to ®bronectin,
however, was also blocked by anti-a5b1 and it is possible that the
results in the migration assay were partly due to inhibition of
adhesion to the ®lters rather than a genuine inhibition of migration.
Effect of avb6 on cell invasion The upregulation of avb6
expression in oral SCC has been consistently demonstrated in vivo
where expression is often strongest at the invasive front of the
tumor (Hamidi et al, 2000). High expression of avb6 in VB6 cells
led to a more invasive phenotype (Fig 5A). Thus VB6 cells were
signi®cantly more invasive than V3 (p = 0.001) and C1 cells (p
< 0.001). These data describing the invasion-promoting activity of
an av integrin in malignant epithelial cells might be compared with
the studies of Danen et al (1995) who demonstrated that malignant
melanoma cell lines expressing avb3 were more invasive than lines
expressing avb5.
Invasion by the VB6 cells could be reduced dramatically using
anti-av or anti-avb6 antibodies whereas anti-av or anti-avb6 had
no effect on the C1 null transfectants or the V3 parental cells
(Fig 5B, C, D), con®rming that the increased invasion by VB6
cells was mediated through avb6. Intriguingly, invasion in the C1
and V3 cells appeared to be partly modulated through a5b1,
whereas inhibition of this integrin produced no signi®cant effect on
VB6 invasion.
The mechanism for the increased invasiveness of VB6 cells is, at
present, unclear. The increased invasiveness of VB6 cells is not
simply a re¯ection of a general increase in cell motility but rather a
speci®c motility advantage as a consequence of avb6 expression as
all the cell lines migrate towards collagen I at similar levels. It is
possible that avb6 may modulate protease expression in a similar
fashion to colon carcinoma cells (Niu et al, 1998).
In summary, the upregulation of avb6 in oral SCC has been
demonstrated in several clinical studies but there are few data to
suggest a possible biologic role (Breuss et al, 1995; Jones et al, 1997;
Hamidi et al, 2000). In this paper we show, for the ®rst time, that in
malignant keratinocytes, high avb6 expression promotes invasion
and migration. This suggests that avb6 may have a speci®c role in
driving oral SCC progression. These results indicate that integrin
changes in tumor tissue may not simply re¯ect cancer development
but may have a causative role in this process.
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